Latent Tuberculosis Infection - Diagnosis and Treatment
DOI:
https://doi.org/10.3889/oamjms.2018.161Keywords:
latent tuberculosis infection, tuberculin skin test, interferon-gamma release assayAbstract
INTRODUCTION: Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens without evidence of clinically manifested active tuberculosis (TB). Diagnosis and treatment for LTBI are important for TB, especially in high-risk populations. Tuberculin skin test (TST) and interferon-gamma release assays (IGRAs) are used to diagnose LTBI.
AIM: The study aims to present the first results with IGRA test compared with TST in the screening of LTBI and the treatment results in the cases with LTBI in Macedonia.
MATERIAL AND METHODS: In this study 73 cases diagnosed and treated with LTBI in 2016 were included. For diagnosis of LTBI, we used TST RT -23 5T.U. and commercial IGRA test such as QuantiFERON-TB Gold In-Tube (QFT-IT).
RESULTS: Out of 73 cases with LTBI, 61.64% were men, and 38.36% were women. Among all age groups, the most frequent were cases between 5 and 14 years old (54.79%). Among the evaluated risk groups for LTBI, the most frequent were children household contacts with pulmonary TB cases (61-83.65%), followed by people living with HIV (9-12.33%) and only 3 cases with other medical reasons. Positive TST had 34 cases (46.57%) and positive IGRA test 25 cases (34.25%). Regarding the treatment regimes, we use two regimes: 50 cases (68.44%) received 6 months daily regime with Isoniazid, and 23 cases (31.51%) received 3 months daily regime with Isoniazid and Rifampicin. Treatment outcomes showed that the most patients completed treatment regimes: 55 (75.34%) and only 10 (13.09%) interrupted the treatment.
CONCLUSION: Despite the progress made in the last few years, several challenges remain to be addressed for better management of LTBI which will contribute to strength TB control in the country.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Global TB report. World Health Organization. Geneva, Switzerland: WHO, 2015.
Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, Goletti D, et al and TBNET. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J. 2009; 33:956–73. https://doi.org/10.1183/09031936.00120908 PMid:19407047
Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol. 1974; 99:131–8. https://doi.org/10.1093/oxfordjournals.aje.a121593 PMid:4810628
Wells CD, Cegielski JP, Nelson LJ, et al. HIV infection and multidrug-resistant tuberculosis—the perfect storm. Journal of Infectious Diseases. 2007; 196(1):S86–S107. https://doi.org/10.1086/518665 PMid:17624830
Guidelines on the management of latent tuberculosis infection. Geneva, Switzerland: WHO, 2015.
End TB Strategy, WHO, 2015.
Person AK, Pettit AC, and Sterling AT. Diagnosis and treatment of latent tuberculosis infection: an update. Curr Respir Care Rep. 2013; 2(4):199-207. https://doi.org/10.1007/s13665-013-0064-y PMid:25298921 PMCid:PMC4185413
Mazurek GH, Jereb J, Vernon A, et al. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Recomm Rep. 2010:1–25. PMid:20577159
Lalvani A, Pareek M. Interferon gamma release assays: principles and practice. Enferm Infecc Microbiol Clin. 2010 Apr; 28(4):245-52. https://doi.org/10.1016/j.eimc.2009.05.012 PMid:19783328
Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, Kampmann B, et al. Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. European Respiratory Journal. 2011; 37(1):88–99. https://doi.org/10.1183/09031936.00115110 PMid:21030451
Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Annals of internal medicine. 2007; 146 (5):340–54. https://doi.org/10.7326/0003-4819-146-5-200703060-00006 PMid:17339619
American Thoracic Society, Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000; 161 (4 pt 2):S221-S247. PMid:10764341
Centers for Disease Control and Prevention CDC. Latent tuberculosis infection: A guide for primary health care providers. MMWR, 2013.
Centers for Disease Control and Prevention CDC. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2011; 60:1650–3. PMid:22157884
Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R, Moro RN, Shang N, Goldberg SV. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA pediatrics. 2015; 169(3):247-55. https://doi.org/10.1001/jamapediatrics.2014.3158 PMid:25580725
Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali H, Memish Z, Khan K, Gardam M, Hoeppner V, Benedetti A. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Annals of internal medicine. 2008; 149(10):689-97. https://doi.org/10.7326/0003-4819-149-10-200811180-00003 PMid:19017587
Denholm JT, McBryde ES, Eisen DP, Penington JS, Chen C and Street AC. Adverse effects of isoniazid preventative therapy for latent tuberculosis infection: a prospective cohort study. Drug Healthc Patient Saf. 2014; 6:145–149. https://doi.org/10.2147/DHPS.S68837 PMid:25364275 PMCid:PMC4211866
Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011; 365:2155–66. https://doi.org/10.1056/NEJMoa1104875 PMid:22150035
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0
